CEL-SCI Corporation Announces Upcoming Investor Conference Presentations
May 02 2018 - 9:00AM
Business Wire
CEL-SCI Corporation (NYSE American: CVM), a Phase 3
cancer immunotherapy biopharmaceutical company, announces today
that Geert Kersten, Chief Executive Officer, will present at the
following conferences:
- 2018 Disruptive Growth & Healthcare
Conference at 4:15 p.m. Eastern Time on Tuesday, May 8, 2018. Mr.
Kersten will also participate in the Disruptive Injectables &
Oncology Panel at 1:15 p.m. Eastern Time on May 8.
- NYC Oncology Investor Conference 2018
at 12:30 p.m. Eastern Time on Wednesday, May 9, 2018
Mr. Kersten’s presentations will be available in the Investor
Relations section of the Company's website at
www.cel-sci.com/investor_relations.html.
About The 2018 Disruptive Growth & Healthcare
Conference
The 2018 Disruptive Growth & Healthcare Conference sponsored
by RHK Capital and ReedSmith offers an opportunity to discover life
science companies focusing on unmet medical needs with disruptive
technologies and business models.
About The NYC Oncology Investor Conference 2018
The NYC Oncology Investor Conference 2018 hosted by OneMed
Forum, and sponsored by the National Foundation for Cancer
Research, the International Cancer Impact Fund, Klosters Innovation
Partners, Wilson Sonsini Law Firm, Torreya Partners, and Marcum is
the leading conference for early-stage private and public cancer
investing.
About CEL-SCI Corporation
CEL-SCI is a Phase 3 cancer immunotherapy company. The Phase 3
study is fully enrolled with 928 patients. When it comes to cancer
immunotherapy, CEL-SCI believes it is most logical to boost the
patient’s immune system while it is still intact in order to have
the greatest possible impact on survival. Therefore, CEL-SCI treats
patients who are newly diagnosed with head and neck cancer with its
lead investigational immunotherapy Multikine (Leukocyte
Interleukin, Injection), BEFORE they have received surgery,
radiation and/or chemotherapy. This approach is unique. Most other
cancer immunotherapies are used only after conventional therapies
have been tried and/or failed. Head and neck cancer represents
about 6% of all cancers. Multikine has received Orphan Drug
designation from the FDA for the treatment of head and neck cancer
patients with advanced squamous cell carcinoma. CEL-SCI has
received patents for Multikine from the US, Europe, China and
Japan.
The Company’s LEAPS technology is being developed as a
therapeutic vaccine for rheumatoid arthritis and is supported by
grants from the National Institutes of Health. The Company has
operations in Vienna, Virginia, and in/near Baltimore,
Maryland.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180502005788/en/
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024